| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LQDA Stock Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Liquidia Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.31 |
| 52 Week High | US$7.78 |
| 52 Week Low | US$2.25 |
| Beta | 0.32 |
| 1 Month Change | 0.57% |
| 3 Month Change | -11.50% |
| 1 Year Change | 95.22% |
| 3 Year Change | -45.82% |
| 5 Year Change | n/a |
| Change since IPO | -52.16% |
Recent News & Updates
Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets
Shareholders might have noticed that Liquidia Corporation ( NASDAQ:LQDA ) filed its quarterly result this time last...
Shareholder Returns
| LQDA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.0% | 0.2% | -2.5% |
| 1Y | 95.2% | 9.9% | -10.4% |
Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: LQDA exceeded the US Market which returned -10.4% over the past year.
Price Volatility
| LQDA volatility | |
|---|---|
| LQDA Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LQDA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: LQDA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 52 | Roger Jeffs | https://www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States.
Liquidia Fundamentals Summary
| LQDA fundamental statistics | |
|---|---|
| Market Cap | US$341.67m |
| Earnings (TTM) | -US$41.34m |
| Revenue (TTM) | US$13.26m |
25.8x
P/S Ratio-8.3x
P/E RatioIs LQDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LQDA income statement (TTM) | |
|---|---|
| Revenue | US$13.26m |
| Cost of Revenue | US$3.02m |
| Gross Profit | US$10.24m |
| Other Expenses | US$51.58m |
| Earnings | -US$41.34m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 77.21% |
| Net Profit Margin | -311.72% |
| Debt/Equity Ratio | 35.2% |
How did LQDA perform over the long term?
See historical performance and comparisonValuation
Is Liquidia undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LQDA ($5.31) is trading below our estimate of fair value ($85.26)
Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LQDA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: LQDA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LQDA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LQDA is overvalued based on its PB Ratio (6.2x) compared to the US Pharmaceuticals industry average (1.7x).
Future Growth
How is Liquidia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
69.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LQDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LQDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LQDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LQDA's revenue (50.1% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: LQDA's revenue (50.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LQDA's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Liquidia performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-4.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LQDA is currently unprofitable.
Growing Profit Margin: LQDA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LQDA is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare LQDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LQDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.5%).
Return on Equity
High ROE: LQDA has a negative Return on Equity (-74.63%), as it is currently unprofitable.
Financial Health
How is Liquidia's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LQDA's short term assets ($62.0M) exceed its short term liabilities ($8.0M).
Long Term Liabilities: LQDA's short term assets ($62.0M) exceed its long term liabilities ($30.2M).
Debt to Equity History and Analysis
Debt Level: LQDA has more cash than its total debt.
Reducing Debt: LQDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LQDA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LQDA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 13% each year.
Dividend
What is Liquidia current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LQDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LQDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LQDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LQDA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LQDA has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Roger Jeffs (59 yo)
0.33
Tenure
US$93,251
Compensation
Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...
Leadership Team
Experienced Management: LQDA's management team is considered experienced (2 years average tenure).
Board Members
Experienced Board: LQDA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LQDA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.
Top Shareholders
Company Information
Liquidia Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Liquidia Corporation
- Ticker: LQDA
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$341.669m
- Shares outstanding: 64.34m
- Website: https://www.liquidia.com
Number of Employees
Location
- Liquidia Corporation
- 419 Davis Drive
- Suite 100
- Morrisville
- North Carolina
- 27560
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/15 00:00 |
| End of Day Share Price | 2022/05/13 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.